Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy.
Saved in:
| Title: | Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy. |
|---|---|
| Authors: | Lowery CD; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Blosser W; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Dowless M; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Renschler M; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Perez LV; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Stephens J; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Pytowski B; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Wasserstrom H; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Stancato LF; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Falcon B; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA. |
| Source: | Oncotarget [Oncotarget] 2019 Sep 17; Vol. 10 (53), pp. 5523-5533. Date of Electronic Publication: 2019 Sep 17 (Print Publication: 2019). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: eCollection Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
